POLY-PRED
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
May 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLY-PRED is an ophthalmic suspension approved in 1963 for eye conditions requiring topical corticosteroid treatment. The drug is a small-molecule corticosteroid formulated as drops for direct ocular delivery. It addresses inflammatory and allergic eye conditions in patients requiring topical anti-inflammatory therapy.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focusing on retention strategies rather than growth initiatives, resulting in smaller commercial headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POLY-PRED offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Roles are primarily focused on managing decline, defending market share, and transitioning patients to successor products or generics.
Brand ManagerField Sales Representative
Worked on POLY-PRED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.